One Year After Vioxx, Pendulum May Be Swinging Back To Efficacy At FDA

One year after the withdrawal of Vioxx, FDA appears to be rebalancing its focus from a heightened emphasis on safety towards a greater appreciation of the emerging efficacy of drugs